Team Leader Systems Pharmacology & Medicine, Bayer AG
(Co-)supervisor of ESR 11.
Dr. Jan Schlender is heading a system pharmacology group at Bayer. In addition, he is a pharmacometric lead in clinical development programmes in therapeutic areas cardiovascular, nephrology, ophthalmology, metabolism and gynecology. He joined Bayer in 2016 as a computational life scientist in 2016. During his time at Bayer, he was and is primarily engaged in pharmacokinetic, pharmacodynamic, systems biology and pharmacology modelling and simulation with an increasing share of pharmacometrics project conception and coordination on the portfolio level as well as strategically developing the scientific and computational platform basis. He is currently supervising 4 PhD students and has previously guided a PostDoc, a PhD student, 4 MSc students and several research interns. Prior to joining Bayer, he studied Pharmacy at the University of Bonn and the National Taiwan University. He obtained an additional master in drug research at the University of Bonn with a research fellowship at the University of Florida, where he conducted a thesis about a physiological-based pharmacokinetic (PBPK) approach for transporter-mediated drug interactions. He obtained a PhD in clinical pharmacy at the University of Bonn in affiliation with Bayer Technology Services. In his thesis he developed and evaluated a PBPK population model for elderly individuals. During his PhD candidature, he had a research fellowship from the biotech company Treeway for studies on immunology and central nervous system mechanisms related to Amyotrophic Lateral Sclerosis.
- Lau, S.W., Schlender, J.F., Slattum, P.W., Heald, D.L. and R. O’Connor-Semmes, R. (2020) Geriatrics 2030: Developing Drugs to Care for Older Persons: A Neglected and Growing Population. Clinical Pharmacology and Therapeutics, 107, pp. 53-56. DOI: 10.1002/cpt.1663
- Schlender, J.F., Teutonico, D., Coboeken, K., Schnizler, K., Eissing, T., Willmann, S., Jaehde, U. and Stass, H. (2018) A physiologically based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life. Clinical Pharmacokinetics, 57, pp. 1613-1634. DOI: 10.1007/s40262-018-0661-6
- Schlender, J.F., Vozmediano, V., Golden, A.G., Rodriguez, M., Samant, T.S., Lagishetty, C.V., Eissing, T. and Schmidt, S. (2018) Current strategies to streamline pharmacotherapy for older adults. European Journal of Pharmaceutical Sciences, 111, pp. 432-42. DOI: 10.1016/j.ejps.2017.10.015
- Lau, S. W., Schlender, J.F., Abernethy, D.R., Burckart, G.J., Golden, A., Slattum, P.W., Stegemann, S. and Eissing, T. (2018) Improving Therapeutics to Better Care for Older Adults and the Young: Report From the American College of Clinical Pharmacology Workshop. The Journal of Clinical Pharmacology, 58, pp. 277-280. DOI: 10.1002/jcph.1024
- Schlender, J.F., Meyer, M., Thelen, K., Krauss, M., Willmann, S., Eissing, T. and Jaehde, U. (2016) Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clinical Pharmacokinetics, 55(12), pp. 1573–1589. DOI: 10.1007/s40262-016-0422-3